| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_56954bf0ecb13b742d8f24d40901b6ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_916075766043ce900399a4c2eee9f054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ee2e6bf22aa04ccbdaca0d07b3975995
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_efa4e58d9ccdf0d44926aa4735647221
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8e0daec85fdd4a4c04e22225e70a5cd9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42c9830b038ed2c5369bf5603b9ded3a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A90-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-755 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-755 |
| filingDate |
2000-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2d53c9cbc5baa6a5a6b851d09531211
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b907d1ec93133e893351b9f9eda13ff2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd8cb1f28bec4a1d03f414f3283f2fbc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab098a0783c5e1c69166cf44f3d04928 |
| publicationDate |
2001-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-0112836-A1 |
| titleOfInvention |
Crystal of a truncated protein construct containing a coagulation factor viii c2 domain in the presence or absence of a bound ligand and methods of use thereof |
| abstract |
A detailed three-dimensional structure for the C-terminal C2 domain of blood coagulation factor VIII is disclosed. The novel truncated factor VIII constructs which were designed so as to omit a significant portion of the flexible full length protein are also part of the present invention. In addition, the crystals of the protein, both in the presence and absence of bound ligands are also included. Furthermore, methods of identifying antagonists of the human factor VIII protein which can be used to inhibit coagulation or to stabilize and activate factor VIII mutants are also disclosed. Furthermore, methods of identifying variations of the C2 domain sequence and structure that can be incorporated into intact factor VIII for the purpose of administration to hemophiliac patients who are immunoreactive against wild type factor VIII are disclosed. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009075772-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0170968-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0170968-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1319016-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1319016-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/HR-P20020767-B1 |
| priorityDate |
1999-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |